PANCREATIC CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Gemzar News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.

June 19, 2018

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer

By Anonymous User anonymous_user_10987

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has been a standard treatment for over a decade. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of […]

View full entry

Tags: Chemotherapy, gemzar, mFOLFIRINOX, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, treatment


A New Standard of Care of Treatment for Resectable Pancreatic Cancer?

June 6, 2016

A New Standard of Care of Treatment for Resectable Pancreatic Cancer?

By Anonymous User anonymous_user_10987

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting the European Study Group for Pancreatic Cancer (ESPAC)-4 has presented results that will change the management of pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the […]

View full entry

Tags: 2016, asco, capecitabine, ESPAC-4, European Study Group for Pancreatic Cancer, gemcitabine, gemzar, immunotherapy, mesothelin-directed cells, News Tips and Features, News Tips and Features Other, Pancreatic Cancer


Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer

September 23, 2014

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer

By Anonymous User anonymous_user_10987

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage, and treatment of advanced disease remains challenging. Gemzar has been a standard chemotherapy drug […]

View full entry

Tags: gemzar, gilead, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, Recurrent Pancreatic Cancer, simtuzuma, Stage IV Pancreatic Cancer


In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival

July 10, 2014

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival

By Anonymous User anonymous_user_10987

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine). These findings were recently published in Journal of Clinical Oncology. Pancreatic cancer is one of the deadliest forms […]

View full entry

Tags: eloxatin, gemzar, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy

July 1, 2014

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy

By Anonymous User anonymous_user_10987

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer was presented recently at the annual American Society of Clinical Oncology meeting in Chicago.1  Results of the study were initially reported in the New England Journal of Medicine.2 Pancreatic cancer […]

View full entry

Tags: abraxane, gemzar, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer


View more articles like this
More news and in-depth Pancreatic Cancer information

CONDITIONS OF THE GI TRACT